本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
歡迎您與家人及摯友一起蒞臨歷奇探索 香港2024年8月7日 /美通社/ -- 香港大富翁夢想世界™創意連連，在這個屢破高溫紀錄的炎熱夏日，推出期間限定的二至四人優惠套票，好讓你與家人及摯友一起探索這個虛擬與真實兼容的大富翁遊戲主題體驗館，套票更額外加送大富翁真人玩遊戲票，大富翁焦糖爆谷及Haagen Daze雪糕杯，精選火熱暑期優惠由即日起至八月三十一日止，您和您的家人及摯友絕對不容錯過! 暑期優惠套票分為兩位，三位及四位入場三款，定價分別為HK$440，HK$660及HK$880，較普通門票大幅折讓，並額外送贈上述遊戲票及精美小食，讓您和您的家人及摯友擁有更完整的富貴體驗。 座落於香港太平山山頂廣場的香港大富翁夢想世界™，是香港備受歡迎的旅遊景點，自開幕以來，一直大受歡迎，已經成為本地訪客及海外遊客必到的旅遊消閒目的地。以大富翁遊戲為設計藍本的體驗館，當然少不了桌上遊戲的實體化場景，最為人熟識的水務局及監獄等逐一呈現，還有大富翁先生的豪華大宅和內裡的珍貴典藏，以及具備先進4D技術的電影院及多個互動AR遊戲…。 此外，香港大富翁夢想世界™提供嶄新的機械人管家服務外，並採用「最高規格」的衛生安全措施，以高科技納米觸媒24小時無菌方案，針對環境和物品表面進行除菌消毒，以最大程度降低病毒感染風險，為遊覽大富翁體驗館的遊客提供安全舒適的玩樂場地。 【關於大富翁夢想世界™】 大富翁夢想世界™ 是全球首間大富翁的主題館，座落於「大富翁：香港版」地位超然、地價最高的「地王」— 香港太平山頂，成為香港及全球嶄新旅遊景點之一。大富翁夢想世界™把桌上遊戲的經典元素立體呈現，充滿驚喜待遊客蒞臨逐發現！人人都可以成為大富翁，歡迎到來一起擁抱夢想！ 有關活動的詳細資訊，歡迎瀏覽大富翁夢想世界™官網: www.monopolydreams.com
Cloudera's latest updates enhance open interoperability while addressing growing demands for data security and governance Platform updates will be on display during EVOLVE24 in Singapore August 6-7 SANTA CLARA, Calif., Aug. 7, 2024 /PRNewswire/ -- Cloudera, the only true hybrid platform for data, analytics and AI, today unveiled two key enhancements to its metadata management solutions. These updates boost open interoperability within the open data lakehouse and address increasing demands for security and governance across the entire data lifecycle. As enterprises invest more in generative AI applications, robust and adaptable metadata management becomes critical for data quality and compliance. However, to be successful and achieve more accurate, scalable outcomes, enterprises need a unified, secure platform that can unleash the transformative power of metadata management. As the platform vendor of choice for data, analytics, and AI at scale for enterprises across all key industry verticals, Cloudera delivers an end-to-end open data lakehouse with open standards that can integrate and interoperate in any ecosystem. The latest updates to support this commitment to modern data architectures include: Cloudera's new Iceberg REST Catalog integration now allows seamless access to Apache Iceberg tables using third-party engines, enabling users to leverage various tools while ensuring unified security and governance. It simplifies data access and maintains data permissions and lineage across platforms, reducing the cost and the risk of data breaches by minimizing the number of separate security layers. Cloudera's Shared Data Experience (SDX) is now in technical preview as a cloud-native, containerized experience that provides end-to-end unified data security, governance, and metadata management, now enhanced for greater elasticity, scale and performance. It provides self-service data access across tools, helps to minimize breach risks by consolidating security functions, and supports single-pane-of-glass management across cloud and on-premises data. In addition to safeguarding data with security and lineage throughout its lifecycle, Cloudera's latest updates enable enterprises to boost performance, scalability, and resiliency while reducing total cost of ownership (TCO) by optimizing metadata management. The expansion also facilitates metadata sharing without creating copies, enabling innovation with third-party tools without vendor lock-in. "There is no moat bigger than your corporate data. Considering this, organizations are asking for a unified way to access and govern every data asset – structured and unstructured, in every location – on-prem and multi cloud, and at every velocity – batch or streaming. Data leaders want a consistent view of data by leveraging open table formats and applying a consistent set of policies regardless of where the content resides," said industry analyst, Sanjeev Mohan. "This is possible through an enhanced data catalog that incorporates formats like Iceberg REST APIs and enables fine-grained access control." "Unified data and interoperability has, and continues to be, central to Cloudera's open data lakehouse architecture across hybrid clouds," said Dipto Chakravarty, Chief Product Officer at Cloudera. "Our platform delivers unmatched scalability, performance, resilience, and cost-efficiency for managing expanding metadata, without vendor lock-in or data silos. By adhering to open standards, we ensure seamless integration and interoperability across any ecosystem so enterprises can make the most of their AI investments." Cloudera will be demonstrating these updates during Cloudera's EVOLVE24 Singapore event - one of the industry's premier Data and AI conference - taking place August 6-7 at the Sands Expo & Convention Center. Attendees will be able to speak to experts onsite about Cloudera's commitment to being the only true hybrid open data lakehouse that brings analytics and AI to business data. For more information on how these advancements enhance Cloudera's dedication to open interoperability while addressing growing demands for security and governance, check out our recent blog. About ClouderaCloudera is the only true hybrid platform for data, analytics, and AI. With 100x more data under management than other cloud-only vendors, Cloudera empowers global enterprises to transform data of all types, on any public or private cloud, into valuable, trusted insights. Our open data lakehouse delivers scalable and secure data management with portable cloud-native analytics, helping to enable customers to bring GenAI models to their data while maintaining privacy and ensuring responsible, reliable AI deployments. The world's largest brands in financial services, insurance, media, manufacturing, and government rely on Cloudera to use their data to solve what seems impossible—today and in the future. To learn more, visit Cloudera.com and follow us on LinkedIn and X. Cloudera and associated marks are trademarks or registered trademarks of Cloudera, Inc. All other company and product names may be trademarks of their respective owners.
Jemperli in combination with chemotherapy is the first immuno-oncology treatment approved in the frontline setting for this patient population in Singapore.[1,2] Latest published local registry reported endometrial cancer as the fourth most common cancer and had the ninth highest cancer mortality rate among females in the country.[3] An estimated 20-29% of all endometrial cancers globally are dMMR/MSI-H.[4] Chemotherapy used alone has been the current standard of care for primary advanced or recurrent endometrial cancer, and many patients eventually experience disease progression.[5] SINGAPORE, Aug. 7, 2024 /PRNewswire/ -- GSK Singapore today announced that the Singapore Health Sciences Authority (HSA) has approved a new indication for Jemperli (dostarlimab), which may now be used in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H).[1] With this approval, Jemperli is now indicated earlier in treatment, in combination with chemotherapy, for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. Jemperli has earlier received approval from Singapore HSA as a monotherapy in adult patients with dMMR recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.[1] Latest Singapore Cancer Registry, from 2017-2021, reported endometrial cancer as the fourth most common and had the ninth highest cancer mortality rate among females in the country, with 3,133 new cases diagnosed during the period.[3] Approximately 15-20% of endometrial cancer patients globally and 28% in Singapore were at advanced disease stage at the time of diagnosis.[3,4] An estimated 20-29% of all endometrial cancers globally are dMMR/MSI-H.[4] Chemotherapy used alone has been the current standard of care for primary advanced or recurrent endometrial cancer, and many patients eventually experience disease progression.[5] Dr. Stephanie Cinthu Stephen Ambrose, GSK Singapore Medical Director, said: "Singapore's expanded regulatory approval of Jemperli redefines the treatment landscape for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in Singapore. Until now, chemotherapy alone has been the standard of care with many patients experiencing disease progression. In GSK's RUBY trial, Jemperli plus chemotherapy demonstrated a 72% reduction in the risk of disease progression or death versus chemotherapy in this patient population, providing a statistically significant and clinically meaningful benefit. These results underscore the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy." Dr. John Chia of Curie Oncology, Singapore, said: "Metastatic endometrial cancer is an aggressive disease with poor outcomes, and doctors sometimes struggle with limited effective treatment options. The results of the RUBY trial represent a clinical breakthrough in decades for dMMR/MSH-I endometrial cancer (or commonly known as uterine cancer). With this new approved treatment combination, many patients with primary advanced or recurrent dMMR endometrial cancer in Singapore will now have an opportunity for potential complete remission, with maximal benefit when given early in the treatment." GSK's submission to the Singapore's regulatory body included interim analysis results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO Phase III trial, which reflect a robust median duration of follow-up of ≥ 25 months. The trial met the primary endpoint of investigator-assessed progression-free survival (PFS), demonstrating a statistically significant and clinically meaningful benefit in patients treated with Jemperli plus carboplatin and paclitaxel in the dMMR/MSI-H population. In the dMMR/MSI-H population, a 72% reduction in the risk of disease progression or death was observed.[1] The safety and tolerability profile for Jemperli plus carboplatin and paclitaxel was generally consistent with the known safety profiles of the individual agents. The most common treatment-emergent adverse events (≥ 20%) in patients receiving Jemperli plus chemotherapy were rash, diarrhoea, hypothyroidism, and hypertension.[1] Artistic representation of endometrial cancer (image by GSK) GSK Asia House Singapore (image by GSK) About endometrial cancer Endometrial cancer is one of the most common gynaecologic cancers in developed countries.[3] According to latest Singapore Cancer Registry data, from 2017-2021, endometrial cancer was the fourth most common cancer and had the ninth highest cancer mortality rate among females.[3] There are about 3,133 new cases of endometrial cancer diagnosed between the 2017 – 2021.[3] Approximately 15-20% of endometrial cancer patients globally and 28% in Singapore were at advanced disease stage at the time of diagnosis.[3,4] An estimated 20-29% of all endometrial cancers globally are dMMR/MSI-H.[4] Chemotherapy used alone has been the current standard of care for primary advanced or recurrent endometrial cancer, and many patients eventually experience disease progression.[5] About RUBY RUBY is a two-part global, randomised, double-blind, multicentre phase III trial of patients with primary advanced or recurrent endometrial cancer. Part 1 is evaluating dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus carboplatin-paclitaxel plus placebo followed by placebo. Part 2 is evaluating dostarlimab plus carboplatin- paclitaxel followed by dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed by placebo. The dual-primary endpoints in Part 1 are investigator-assessed PFS based on the Response Evaluation Criteria in Solid Tumours v1.1 and OS. The statistical analysis plan included pre-specified analyses of PFS in the dMMR/MSI- H and ITT populations and OS in the overall population. Pre-specified exploratory analyses of PFS in the mismatch repair proficient (MMRp)/microsatellite stable (MSS) population and OS in the dMMR/MSI-H populations were also performed. RUBY Part 1 included a broad population, including histologies often excluded from clinical trials and had approximately 10% of patients with carcinosarcoma and 20% with serous carcinoma. In Part 2, the primary endpoint is investigator-assessed PFS. Secondary endpoints in Part 1 and Part 2 include PFS per blinded independent central review, overall response rate, duration of response, disease control rate, patient-reported outcomes, and safety and tolerability. The RUBY trial data (https://www.gsk.com/en-gb/media/press-releases/phase-iii-ruby-clinical-trial-demonstrates- potential-of-Jemperli-plus-chemotherapy-to-redefine-the-treatment-of-primary-advanced-or-recurrent-endometrial- cancer/) were presented at the European Society for Medical Oncology (ESMO) Virtual Plenary and Society of Gynecologic Oncology (SGO) Annual Meeting on 27 March 2023, and were simultaneously published in The New England Journal of Medicine. About Jemperli (dostarlimab) Jemperli is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.[6] In Singapore, Jemperli is indicated in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR, or microsatellite instability-high (MSI-H), and as a single agent for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. Jemperli was discovered by AnaptysBio, Inc. and licensed to TESARO, Inc., under a collaboration and exclusive license agreement signed in March 2014. Information on indication, dosing, and contraindications per Singapore's National Drug Formularywww.ndf.gov.sg/monograph/detail/M01739 GSK in Oncology GSK is committed to maximising patient survival through transformational medicines, with a current focus on breakthroughs in immuno-oncology and tumour-cell targeting therapies, and development in haematologic malignancies, gynaecologic cancers, and other solid tumours. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at https://www.gsk.com/en-gb/locations/singapore/ For media queries, please contact: Rommel AbudaGSK Singaporerommel.j.abuda@gsk.com Rae Chew (on behalf of GSK Singapore)PR Raerae.chew@pr-rae.com References 1 Jemperli (dostarlimab) Singapore Prescribing Information, 2024. 2 HSA infosearch: https://www.hsa.gov.sg/e-services/infosearch 3 Singapore Cancer Registry Annual Report, 2021 4 Bonneville R. JCO precision oncology. 2017;2017;1-15 5 Miller DS. J Clin Oncol. 2020;38;3841-3850 6 Laken H, Kehry M, Mcneeley P, et al. Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody. European Journal of Cancer. 2016;69, S102. doi:10.1016/s0959-8049(16)32902-1.
MANILA, Philippines, Aug. 7, 2024 /PRNewswire/ -- ADP, a global leader in payroll and human capital management solutions, announces the rollout of ADP SecurTime, its cloud-based time and attendance solution, in the Philippines. This rollout aims to streamline payroll and workforce management process capabilities for businesses across the Philippines. ADP SecurTime, acquired by ADP in 2023, offers robust cloud-based time tracking, attendance management, and workforce management software. It provides businesses with a range of intuitive and insightful features, including: Capture real-time attendance: Utilises biometrics, tablet or mobile phone for real-time tracking Time fraud prevention: Features geo-tagging, geo-fencing, live tracking and alerts Integrated payroll and time: Reduces potential pay inaccuracies and administrative time Centralized dashboard: Offers reports and analytics to identify patterns and discrepancies "We are proud to introduce ADP SecurTime to the Philippines, empowering businesses with a state-of-the-art time and attendance solution tailored to meet the unique challenges of managing a diverse workforce," said Jessica Zhang, Senior Vice President of APAC at ADP. "By integrating our robust payroll solutions with ADP SecurTime, businesses in the Philippines can enhance efficiency and accuracy in workforce management. This powerful combination reduces administrative burdens and saves costs, enabling companies to focus more on strategic growth and employee satisfaction." "The rollout also underscores our commitment to supporting businesses with innovative solutions that drive productivity and compliance," added Zhang. ADP provides services to a wide range of businesses and industries, helping organizations manage their payroll, HR, time, tax, and benefits needs. Serving more than one million clients in 140 countries, ADP has the experience and scale to support businesses of all sizes – from small business to global enterprise – across all industries. About ADP (NASDAQ – ADP) Designing better ways to work through cutting-edge products, premium services and exceptional experiences that enable people to reach their full potential. HR, Talent, Time Management, Benefits and Payroll. Informed by data and designed for people. Learn more at ADP.com ADP, the ADP logo, and Always Designing for People are trademarks of ADP, Inc. Copyright © 2024 ADP, Inc. All rights reserved.
TAIPEI and SAN DIEGO, Aug. 7, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced receipt of a "Study May Proceed" letter from the U.S. Food and Drug Administration ("FDA") for the initiation of a Phase I/II clinical study of Silmitasertib (CX-4945) for the treatment of children and young adults with relapsed refractory solid tumors. The principal investigator of this investigator-initiated trial (IIT), Dr. Giselle Saulnier Sholler, is an internationally known pediatric hematology-oncology clinician and researcher. In August 2023, she was invited to serve as the division chief of Pediatric Hematology and Oncology at Penn State Health Children's Hospital. She brought with her the Beat Childhood Cancer Research Consortium, a worldwide network of more than 55 universities and children's hospitals dedicated to discovering new therapies and cures for children with cancer. The research consortium has enrolled more than 1,800 pediatric cancer patients in more than 23 trials, and has previously helped a drug obtain FDA approval for high-risk relapsed neuroblastoma treatments. This phase I/II study is funded by the Four Diamonds Foundation, with Senhwa Biosciences providing the investigational drug, Silmitasertib (CX-4945). Senhwa Biosciences is planning to apply for Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPD) for Silmitasertib (CX-4945) for the treatment of neuroblastoma. If these designations are granted and the drug is successfully commercialized, the company would obtain a Priority Review Voucher (PRV). The holder of a PRV can designate any future human drug application to receive priority review, potentially shortening the review time to 6 months, which could accelerate the timeline for the company (or its partners) to bring other products to market. The clinical trial design also includes Ewing's sarcoma and osteosarcoma, which are common pediatric bone cancers with poor prognoses, representing unmet medical needs.
Highlighting innovations in AI, cloud-based manufacturing execution system (MES), and cybersecurity, the event promotes digital transformation and sustainability in the manufacturing sector SURABAYA, Indonesia, Aug. 7, 2024 /PRNewswire/ -- Rockwell Automation, the world's largest company dedicated to industrial automation and digital transformation, hosted its ROKLive Southeast Asia event in Surabaya, Indonesia, on August 7, 2024. With the theme 'Discover What's Possible' – the event showcased the latest innovations in industrial technology such as Artificial Intelligence (AI), cloud-based manufacturing execution systems (MES), and cybersecurity, while putting the spotlight on the future of industrial operations. ROKLive, Rockwell Automation's event for partners and customers, showcases the latest innovations in industrial automation, digital transformation, and smart manufacturing solutions. The event, encourages partners and customers to dream big, presenting an opportunity to educate themselves on transformative technologies like AI, Augmented Reality/Virtual Reality (AR/VR), and robotics, discovering how these innovations can help revolutionize their business. The event featured engaging presentations, customer experience sharing, technology updates, industry-focus discussions, and an interactive expo featuring the latest innovations from Rockwell Automation and members of its PartnerNetwork™. Sustainability, cybersecurity, and emerging technologies in digital transformation were among the key points of discussion in the sessions. Marcelo Tarkieltaub, regional director, Southeast Asia for Rockwell Automation delivered a keynote on the future of automation, highlighting its potential to drive greater innovation, adaptability, and performance in ever-more complex industrial settings. "Automation is transforming industrial environments by simplifying complexity and enhancing innovation, flexibility, and performance. As transformative technologies continue to emerge, business leaders must stay informed and adapt to remain competitive," said Marcelo. In the face of global challenges like inflation and supply chain disruptions, the manufacturing sector is increasingly relying on technology to boost productivity, tackle skilled labour shortages, and enhance cybersecurity. The latest State of Smart Manufacturing Report by Rockwell Automation foregrounded a rising emphasis on AI and machine learning among manufacturers. In the Asia Pacific region, 44% of companies surveyed are already beginning to integrate AI and machine learning into their operations. Indonesia gears up for the future of manufacturing The manufacturing sector is vital to Indonesia's social and economic development. Today, it is the largest GDP contributor and dominates the export landscape. The Indonesian government has launched Making Indonesia 4.0, a roadmap to prepare for the digital industrial era. It targets seven key manufacturing sectors: food and beverage, textiles and clothing, automotive, chemicals, electronics, medical devices, and pharmaceuticals. These sectors account for 70% of industrial GDP, 65% of industrial exports, and employ 60% of the industrial workforce, ensuring a comprehensive approach to digital readiness and competitiveness. The Indonesian Digital Industry Centre PIDI 4.0 offers strategic programs to drive digital transformation, including training and upskilling human resources for Industry 4.0. This program has attracted thousands of participants nationwide, focusing on developing essential skills and competencies for the digital age. "At ROKLive Surabaya, attendees witnessed the transformative potential of enterprise connectivity, which provides data-driven insights for real-time, informed decision-making to achieve better outcomes. The local Indonesian manufacturing industry is growing in size and sophistication in part because of its enthusiastic embrace of technology," said Adi Darmadi, country manager, Indonesia, Rockwell Automation. For more information about ROKLive Surabaya, please visit the official website. About Rockwell AutomationRockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 29,000 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise to life across industrial enterprises, visit www.rockwellautomation.com.
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
